2-Deoxy-D-ribose Clinical Trials

Size	Price	Qty
100mg	USD 97

Clinical Trials

Multiple clinical trials are evaluating therapeutic applications of 2-Deoxy-D-ribose across distinct medical indications. A completed Phase 3 trial sponsored by Shire and Takeda investigated strategies for managing Cytomegalovirus infection, while an actively recruiting trial sponsored by Kasr El Aini Hospital is evaluating a topical 2-Deoxy-D-ribose hydrogel formulation against minoxidil for androgenic alopecia. Spanning both industry and academic sponsors, these studies highlight efforts to address viral conditions and dermatological hair loss disorders.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07502976	RECRUITING	Androgenic Alopecia	Kasr El Aini Hospital	2026-01-01
NCT02927067	Completed	Cytomegalovirus (CMV)	Shire\|Takeda Development Center Americas Inc.\|Takeda	2017-04-14	Phase 3

(data from https://clinicaltrials.gov, updated on 2026-04-06)

Check the 2-Deoxy-D-ribose product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As an endogenous monosaccharide metabolite, 2-deoxy-D-ribose stimulates purine nucleoside phosphorylase-mediated pathways to promote vascular endothelial growth factor expression and intracellular signaling. This upregulation of pro-angiogenic activity drives localized capillary formation and hair follicle reactivation, providing the biochemical foundation for its clinical evaluation in managing androgenic alopecia.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).